GLPwatch

The investigation of therapeutic potential of oxytocin and liraglutide on vincristine-induced neuropathy in rats.

J Biochem Mol Toxicol · 2020

Last updated 2026-05-28

In a rat study, vincristine (a chemotherapy drug) caused nerve damage, leading to changes in nerve function, poorer movement, and chemical imbalances in the nerves. However, when rats were also given either oxytocin or liraglutide (a GLP-1 drug), these side effects were reduced, including better nerve function, less nerve damage, and improved nerve growth factors compared to rats given only vincristine.

AI summary of the abstract below.

JournalJ Biochem Mol Toxicol, 2020
Citations11
Relative citation ratio0.82
NIH percentile44
Molecules liraglutide

Abstract

The aim of this study was to assess the therapeutic potential of oxytocin and liraglutide (LIR), a GLP-1 analogue, in a rat model of vincristine-induced neuropathy. Rats were injected with vincristine (VCR) at a dose of 4 mg/kg twice a week for 5 weeks. The VCR-administered rats were divided into three groups and received saline, oxytocin, or liraglutide simultaneously with VCR. After the treatment period, electrophysiological, biochemical, histological, and immunohistochemical investigations were performed. Electromyography (EMG) recordings demonstrated significant alterations in the VCR + saline group (p < .001). Also, motor performance was decreased in the VCR + saline group (p < .05). Histologically, the axonal diameter was decreased in all groups. VCR + saline group showed significantly increased lipid peroxidation and decreased nerve growth factor (NGF) expression. However, the administration of oxytocin and liraglutide significantly prevented the EMG alterations, lipid peroxidation, and reduction in neuronal NGF expression. On the basis of these findings, oxytocin and liraglutide may be considered as potential agents for the prevention of VCR-induced neuropathy.

Verbatim abstract via PubMed 31682045 ↗

Related research